Abrahamsson et al. (39) showed that CD8+CD28−CD57+ T cell subsets were persistently increased in MS patients after AHSCT and were able to suppress CD4+ T cell proliferation with variable potency (17). This evidence concerns the gene CD8A and myeloid sarcoma.